Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A case of transcatheter closure of inferior vena cava type atrial septal defect with patent ductus arteriosus occlusion device guided by 3D printing technology].

Zhonghua xin xue guan bing za zhi·2015
Same author

Visual Tracking Based on the Adaptive Color Attention Tuned Sparse Generative Object Model.

IEEE transactions on image processing : a publication of the IEEE Signal Processing Society·2015
Same author

Comparative genomic analysis reveals bilateral breast cancers are genetically independent.

Oncotarget·2015
Same author

Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

International journal of clinical and experimental medicine·2015
Same author

The cardioprotective effect of hypoxic and ischemic preconditioning in dogs with myocardial ischemia-reperfusion injury using a double-bypass model.

Life sciences·2015
Same author

The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis.

The Annals of thoracic surgery·2015

Related Experiment Videos

Propofol pharmacokinetics in China: a multicentric study.

Hong-Bo Ye1, Jin-Heng Li, Jian-Zhong Rui

  • 1Department of Pharmacology, Jinling Hospital, Nanjing city, Jiangsu, China.

Indian Journal of Pharmacology
|June 16, 2012
PubMed
Summary

A new population pharmacokinetic model for propofol was developed using a three-compartment model. This model accurately describes propofol

Keywords:
Propofolmulticenternonlinear mixed effect model

Related Experiment Videos

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Anesthesiology
  • Mathematical Modeling

Background:

  • Propofol is a widely used anesthetic agent.
  • Accurate pharmacokinetic models are crucial for optimizing propofol dosing.
  • Existing models may not fully capture inter-individual variability.

Purpose of the Study:

  • To establish a new, robust population pharmacokinetic model for propofol.
  • To identify key covariates influencing propofol pharmacokinetics.
  • To validate the model's predictive performance.

Main Methods:

  • A multicenter study involving 220 participants and 3259 blood samples.
  • Propofol concentrations measured using HPLC-UV, HPLC-FLU, and GC-MS.
  • Nonlinear mixed-effects modeling (NONMEM) applied to analyze concentration-time data.
  • Covariate modeling using a stepwise approach with PsN and PDx for validation.

Main Results:

  • A three-compartment model with first-order elimination best described propofol pharmacokinetics.
  • Key covariates identified: age, body weight, and sex.
  • Model parameters (CL, V1, Q2, V2, Q3, V3) were estimated with associated inter-individual variability.
  • Bootstrap and visual predictive checks confirmed model stability and accuracy.

Conclusions:

  • The developed three-compartment model provides a reliable description of propofol pharmacokinetics.
  • Age, body weight, and sex significantly influence propofol disposition.
  • The model is validated and suitable for clinical application in optimizing propofol anesthesia.